Biologiska och kliniska aspekter av myelodysplastiskt syndrom – Magnus Tobiassons forskargrupp

Publikationer

Utvalda publikationer

• Letter: BLOOD. 2021;137(9):1260-1263

  Absence of a common founder mutation in patients with cooccurring myelodysplastic syndrome and plasma cell disorder.

  Klimkowska M; Nannya Y; Gran C; Månsson R; Douagi I; Ogawa S; Nahi H; Tobiasson M
• Article: JOURNAL OF MOLECULAR DIAGNOSTICS. 2021;23(3):347-357

  Multicenter Next-Generation Sequencing Studies between Theory and Practice: Harmonization of Data Analysis Using Real-World Myelodysplastic Syndrome Data.

  Sandmann S; de Graaf AO; Tobiasson M; Kosmider O; Abáigar M; Clappier E; Gallì A; van der Reijden BA; Malcovati L; Fenaux P; Díez-Campelo M; Fontenay M; Hellström-Lindberg E; Jansen JH; Dugas M
• Article: NATURE MEDICINE. 2020;26(10):1549-1556

  Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes.

  Bernard E; Nannya Y; Hasserjian RP; Devlin SM; Tuechler H; Medina-Martinez JS; Yoshizato T; Shiozawa Y; Saiki R; Malcovati L; Levine MF; Arango JE; Zhou Y; Solé F; Cargo CA; Haase D; Creignou M; Germing U; Zhang Y; Gundem G; Sarian A; van de Loosdrecht AA; Jädersten M; Tobiasson M; Kosmider O; Follo MY; Thol F; Pinheiro RF; Santini V; Kotsianidis I; Boultwood J; Santos FPS; Schanz J; Kasahara S; Ishikawa T; Tsurumi H; Takaori-Kondo A; Kiguchi T; Polprasert C; Bennett JM; Klimek VM; Savona MR; Belickova M; Ganster C; Palomo L; Sanz G; Ades L; Della Porta MG; Elias HK; Smith AG; Werner Y; Patel M; Viale A; Vanness K; Neuberg DS; Stevenson KE; Menghrajani K; Bolton KL; Fenaux P; Pellagatti A; Platzbecker U; Heuser M; Valent P; Chiba S; Miyazaki Y; Finelli C; Voso MT; Shih L-Y; Fontenay M; Jansen JH; Cervera J; Atsuta Y; Gattermann N; Ebert BL; Bejar R; Greenberg PL; Cazzola M; Hellström-Lindberg E; Ogawa S; Papaemmanuil E
• Review: HAEMATOLOGICA. 2020;105(7):1765-1779

  Myelodysplastic syndromes: moving towards personalized management.

  Hellström-Lindberg E; Tobiasson M; Greenberg P
• Letter: LEUKEMIA & LYMPHOMA. 2019;60(13):3316-3319

  Angioimmunoblastic T-cell lymphoma and myelodysplastic syndrome with mutations in TET2, DNMT3 and CUX1 - azacitidine induces only lymphoma remission.

  Tobiasson M; Pandzic T; Cavelier L; Sander B; Wahlin BE
• Review: JOURNAL OF INTERNAL MEDICINE. 2019;286(1):41-62

  Treatment of myelodysplastic syndrome in the era of next-generation sequencing.

  Tobiasson M; Kittang AO
• Article: LEUKEMIA. 2019;33(2):522-527

  Male sex and the pattern of recurrent myeloid mutations are strong independent predictors of blood transfusion intensity in patients with myelodysplastic syndromes.

  Rydén J; Edgren G; Karimi M; Walldin G; Tobiasson M; Wikman A; Hellström-Lindberg E; Höglund P
• Article: ONCOLOGIST. 2018;23(2):159-170

  Azacitidine in Lower-Risk Myelodysplastic Syndromes: A Meta-Analysis of Data from Prospective Studies.

  Komrokji R; Swern AS; Grinblatt D; Lyons RM; Tobiasson M; Silverman LR; Sayar H; Vij R; Fliss A; Tu N; Sugrue MM
• Article: BLOOD. 2017;130(7):881-890

  SF3B1-initiating mutations in MDS-RSs target lymphomyeloid hematopoietic stem cells.

  Mortera-Blanco T; Dimitriou M; Woll PS; Karimi M; Elvarsdottir E; Conte S; Tobiasson M; Jansson M; Douagi I; Moarii M; Saft L; Papaemmanuil E; Jacobsen SEW; Hellström-Lindberg E
• Article: CELL REPORTS. 2017;20(3):572-585

  Integrative Genomics Identifies the Molecular Basis of Resistance to Azacitidine Therapy in Myelodysplastic Syndromes.

  Unnikrishnan A; Papaemmanuil E; Beck D; Deshpande NP; Verma A; Kumari A; Woll PS; Richards LA; Knezevic K; Chandrakanthan V; Thoms JAI; Tursky ML; Huang Y; Ali Z; Olivier J; Galbraith S; Kulasekararaj AG; Tobiasson M; Karimi M; Pellagatti A; Wilson SR; Lindeman R; Young B; Ramakrishna R; Arthur C; Stark R; Crispin P; Curnow J; Warburton P; Roncolato F; Boultwood J; Lynch K; Jacobsen SEW; Mufti GJ; Hellstrom-Lindberg E; Wilkins MR; MacKenzie KL; Wong JWH; Campbell PJ; Pimanda JE
• Article: ONCOTARGET. 2017;8(17):28812-28825

  Comprehensive mapping of the effects of azacitidine on DNA methylation, repressive/permissive histone marks and gene expression in primary cells from patients with MDS and MDS-related disease.

  Tobiasson M; Abdulkadir H; Lennartsson A; Katayama S; Marabita F; De Paepe A; Karimi M; Krjutskov K; Einarsdottir E; Grövdal M; Jansson M; Ben Azenkoud A; Corddedu L; Lehmann S; Ekwall K; Kere J; Hellström-Lindberg E; Ungerstedt J
• Article: ONCOTARGET. 2016;7(16):22103-22115

  Mutations in histone modulators are associated with prolonged survival during azacitidine therapy.

  Tobiasson M; McLornan DP; Karimi M; Dimitriou M; Jansson M; Ben Azenkoud A; Jädersten M; Lindberg G; Abdulkadir H; Kulasekararaj A; Ungerstedt J; Lennartsson A; Ekwall K; Mufti GJ; Hellström-Lindberg E
• Article: BLOOD CANCER JOURNAL. 2014;4(3):e189

  Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial.

  Tobiasson M; Dybedahl I; Holm MS; Karimi M; Brandefors L; Garelius H; Grövdal M; Högh-Dufva I; Grønbæk K; Jansson M; Marcher C; Nilsson L; Kittang AO; Porwit A; Saft L; Möllgård L; Hellström-Lindberg E
• Article: MEDICAL ONCOLOGY. 2010;27(1):105-107

  High prevalence of restless legs syndrome among patients with polycytemia vera treated with venesectio.

  Tobiasson M; Alyass B; Söderlund S; Birgegård G

Medlemmar och kontakt

Gruppledare

• 

  Magnus Tobiasson

  Anknuten till Forskning | Docent

  Telefon +46852483702

  E-postadress magnus.tobiasson@ki.se

Alla medlemmar i gruppen

• 

  Magnus Tobiasson

  Anknuten till Forskning | Docent

  Telefon +46852483702

  E-postadress magnus.tobiasson@ki.se
• 

  Joel Wiggh

  Anknuten till Forskning

  E-postadress joel.wiggh@ki.se